FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ajay Kakkar

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Phenomena

Co-author Network

Publications

TOP 3
Giancarlo Agnelli; Umesh Chaudhari; William Fisher; Daniel J George; Ajay K Kakkar; Michael R Lassen; Francesca Lawson; Patrick Mismetti; Patrick Mouret; Alexander G G Turpie
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
Wolfgang Mueck; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Eva Muelhofer; Frank Misselwitz; Bengt I Eriksson
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ajay Kakkar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Giancarlo Agnelli; Umesh Chaudhari; William Fisher; Daniel J George; Ajay K Kakkar; Michael R Lassen; Francesca Lawson; Patrick Mismetti; Patrick Mouret; Alexander G G Turpie
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
The New England journal of medicine 2012;366(7):601-9.
2008: Wolfgang Mueck; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Eva Muelhofer; Frank Misselwitz; Bengt I Eriksson
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thrombosis and haemostasis 2008;100(3):453-61.
2008: Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
The New England journal of medicine 2008;358(26):2765-75.
2008: Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Clinical pharmacokinetics 2008;47(3):203-16.
2007: Giancarlo Agnelli; Alexander Gallus; Samuel Z Goldhaber; Sylvia Haas; Menno V Huisman; Russel D Hull; Ajay K Kakkar; Frank Misselwitz; Sebastian M Schellong
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Circulation 2007;116(2):180-7.
2007: Sebastian M Schellong; Jan Beyer; Ajay K Kakkar; Kai Halbritter; Bengt I Eriksson; Alexander G G Turpie; Frank Misselwitz; Peter Kälebo
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
Journal of thrombosis and haemostasis : JTH 2007;5(7):1431-7.
2007: William D Fisher; Bengt I Eriksson; Kenneth A Bauer; Lars C Borris; Ola E Dahl; Michael Gent; Sylvia Haas; Martin Homering; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Thrombosis and haemostasis 2007;97(6):931-7.
2007: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Frank Misselwitz; Eva Muehlhofer; Peter Kälebo
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thrombosis research 2007;120(5):685-93.
2006: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Eva Muehlhofer; Christoph Dierig; Frank Misselwitz; Peter Kälebo
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Circulation 2006;114(22):2374-81.
2006: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Frank Misselwitz; Peter Kälebo
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Journal of thrombosis and haemostasis : JTH 2006;4(1):121-8.